IN8bio, Inc.
NASDAQ: INAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tai-Wei
- Employees
- 18
- Headquarters
- New York City, United States
- IPO year
- 2021
- Market cap
- $14.6M
- Website
- https://in8bio.com
Loading INAB…
Loading profile data…Frequently asked questions about INAB
What does IN8bio, Inc. (INAB) do?
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetic...
Where does INAB trade?
IN8bio, Inc. (INAB) trades on the NASDAQ Global Market.
What sector is INAB in?
IN8bio, Inc. (INAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IN8bio, Inc.?
Tai-Wei is the chief executive officer of IN8bio, Inc. (INAB).
Where is IN8bio, Inc. headquartered?
IN8bio, Inc. is headquartered in United States.
Does INAB pay a dividend?
IN8bio, Inc. (INAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INAB go public?
IN8bio, Inc. (INAB) completed its initial public offering in 2021.